Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Trends That Matter for Antipsychotic Treatments

Posted by Matt Breese on Oct 12, 2017

Atypical antipsychotics, also known as second-generation antipsychotics, are commonly used to treat conditions such as schizophrenia, bipolar disorder, severe cases of dementiaanxiety disorder and autism.

Clinicians today tend to prescribe atypical antipsychotics instead of typical antipsychotics, which are first-generation treatment options. Industry trends also reveal an increasing range of on-label and off-label uses, according to a report published by the National Center for Biotechnology Information.

Read More

Topics: Specialty, Market Access

Perspectives on Value Frameworks

Posted by Matt Breese on Oct 10, 2017

The pharma industry is experiencing increasing demand from the public and regulatory agencies to define and measure the value of their treatments. Pharma manufacturers today must understand the requirements of many different stakeholders.

The increasing public concern over healthcare costs has led some organizations to define their value frameworks more clearly. Healthcare value frameworks are intended to ensure patients have access to effective, high-quality and responsibly priced treatment options. 

Read More

Topics: Market Access

Formulary Coverage Changes for 2018 Medicare

Posted by Matt Breese on Oct 8, 2017

Over the past couple of years, pharma has seen major shifts in how Medicare sponsors have changed their coverage methodologies. In addition, overall coverage of trending disease areas for Medicare formularies has shifted.

For instance, we've seen major shifts for asthma and COPD treatments within Medicare Part D - with a significant increase in the percentage of lives either not covered or restricted by PAs and step edits.

Read More

Topics: Specialty, Industry Trends, Market Access

MMIT Reality Check on Respiratory (Asthma/COPD) (Oct 2017)

Posted by Matt Breese on Oct 6, 2017

According to our recent payer coverage analysis for asthma and COPD treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing

Trends That Matter for STEM Opportunities

Posted by Matt Breese on Oct 5, 2017

In our weekly Trends that Matter series, we provide infographics, articles and recent news from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is STEM opportunities. Since the pharma industry relies heavily on technology and innovation for economic development, a skilled STEM workforce is essential.

There are many opportunities to build a prosperous career in the STEM fields. According to a report by the U.S. Bureau of Labor Statistics, the national average wage for STEM occupations is nearly double the national average wage for the non-STEM professions.

Read More

Topics: Industry Trends

MMIT Reality Check on Antipsychotics (Oct 2017)

Posted by Matt Breese on Oct 5, 2017

According to our recent payer coverage analysis for atypical antipsychotic treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing

Perspectives on Pharma Sales Planning

Posted by Matt Breese on Oct 3, 2017

Market changes and technological advancements are changing the structure of the pharmaceutical sales force. More and more clinicians are turning to digital channels for treatment awareness and education around current options for specific disease areas to improve patient outcomes.

By adopting eDetailing strategies, pharma reps can better connect with healthcare professionals online. 

Read More

Topics: Branding & Marketing

MMIT Reality Check on Detoxification Agents (Oct 2017)

Posted by Matt Breese on Oct 1, 2017

According to our recent payer coverage analysis for detoxification agents, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing

Trends That Matter for Customer Centricity in Pharma

Posted by Matt Breese on Sep 28, 2017

In our weekly Trends that Matter series, we provide infographics, articles and recent news from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is how the pharma industry can shift away from brand centricity and adopt a more customer-centric approach.

The pharmaceutical industry has been significantly slower to adopt a customer-centric approach than other industries. In the case of pharma, HCPs are considered one group of "customers." According to Kevin Troyanos' recent piece in Pharma Exec MagazineHCPs today expect more personalized messaging and less generic sales tactics. 

Read More

Topics: Industry Trends, Branding & Marketing

Perspectives on Top Therapy Areas

Posted by Matt Breese on Sep 26, 2017

Many new pharmaceutical treatment options have been introduced to the market this year. Areas such as oncology, anti-rheumatics, and anti-virals are driving growth in the industry. However, oncology remains the top therapeutic area with a worldwide market share of 11.7%. 

The industry has seen momentum from investment in the development of new drugs in these key therapeutic areas. This innovation is also leading to increased prescription drug sales. According to the QuintilesIMS National Prescription Audit database, the total retail sales for prescription drugs filled at pharmacies in the U.S. totaled $379,247,789,544 in the 2016 calendar year.

Read More

Topics: Industry Trends